Latest Industry Insights

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the biological, clinical and technological frontiers shaping the next generation of ADCs.

To explore how the CGT landscape is evolving, Technology Networks spoke with Betty Woo, vice president of Cell, Gene and Advanced Therapies at Thermo Fisher Scientific.

In this interview, Technology Networks talked to Dr. Stacy Lindborg, president, chief executive officer and board member at IMUNON, Inc., who shares how its PlaCCine® platform could reshape vaccine development.

The limitations of traditional cryopreservation are becoming increasingly apparent. In this interview, Alastair Carrington, CEO of Atelerix, explores how hypothermic preservation technology is transforming biopreservation.

In this article, Cristiana Bercea discusses how large, automated storage solutions are helping companies to save time, unlock greater efficiency and better meet sustainability goals – without increasing risk.

Dalip Sethi provides valuable insights on how AI is currently being carefully and critically considered within the cell and gene therapy industry, with regard to data and technological preparedness.

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

A specialist in flow cytometry, cell sorting and cellular biology, Dr. Richard Cuthbert shared his perspectives on the current and future applications of flow cytometry – and automated flow cytometry systems – in modern drug discovery.

Dr. Bo Wiinberg, chief business development officer at the Novo Nordisk Foundation Cellerator, discusses the current obstacles halting advances in stem cell-based cell therapies and what can be done to overcome them.

Technology Networks spoke to Professor Thomas Rademacher, co-founder, executive director and CEO at Gylden Pharma Limited, to learn more about T-cell priming vaccine technology and its potential to strengthen preparedness for future pandemics.